<DOC>
	<DOCNO>NCT00909857</DOCNO>
	<brief_summary>To investigate potential benefit new oral contraceptive ( SH T00658ID ) alleviate complaint dysmenorrhea associate oral contraceptive use .</brief_summary>
	<brief_title>Effect Primary Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Otherwise healthy female subject request contraception suffer primary dysmenorrhea sum score dysmenorrheic pain intensity &gt; /= 8 2 baseline cycle document prospective selfrated sum pain score Age : 14 50 year ( inclusive ; smoker must older 30 year ) time point inform consent Normal cervical smear require followup ( cervical smear take screen visit , normal result available document within last 6 month screen visit ) Women cyclic menstrual bleeding , define cycle length 25 35 day amenorrheic cycle cycle without withdrawal bleeding last 3 month prior visit 1 . Able tolerate ibuprofen willing use Ibuprofen supply study . Pregnancy lactation ( delivery , abortion , lactation within three cycle start treatment ) Obesity : body mass index ( BMI ) &gt; 32 kg/m2 Hypersensitivity study drug ingredient Any disease condition might interfere conduct study interpretation result Presence history venous arterial thrombotic / thromboembolic event ( e.g . deep venous thrombosis , pulmonary embolism , myocardial infarction ) cerebrovascular accident , include prodromi ( e.g . transient ischemic attack , angina pectoris ) , condition could increase risk suffer mention disorder , e.g . family history indicate hereditary predispositionUndiagnosed abnormal genital bleeding Abuse alcohol , drug , medicine ( e.g . laxative ) Other contraceptive method : Sterilization Oral , vaginal transdermal hormonal contraception treatment Intrauterine device ( IUD ) without hormone release still place within 30 day visit 1 Simultaneous participation another clinical trial participation another clinical trial prior study entry might impact study objective discretion investigator Major surgery schedule study period</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Primary Dysmenorrhea</keyword>
	<keyword>Oral Contraception</keyword>
</DOC>